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Background: Individuals with a learning disability (LD) are at higher risk of developing type 2 diabetes, but LD is
not straightforward to define or identify, especially at the milder end of the spectrum, which makes case finding
difficult. While supported self-management of health problems is now established, current material is largely
educational and didactic with little that facilitates behavioural change. The interaction between the person with
diabetes and others supporting their care is also largely unknown. For these reasons, there is considerable work
needed to prepare for a definitive trial. The aim of this paper is to publish the abridged protocol of this preparatory
work.
Methods/Design: Phase I is a prospective case-finding study (target n = 120 to 350) to identify and characterise
potential participants, while developing a standardised supported self-management intervention. Phase II is a
randomised feasibility trial (target n = 80) with blinded outcome assessment. Patients identified in Phase I will be
interviewed and consented prior to being randomised to (1) standard treatment, or (2) supported self-management.
Both arms will also be provided with an ‘easy read’ accessible information resource on managing type 2 diabetes. The
intervention will be standardised but delivered flexibly depending on patient need, including components for
the participant, a supporter, and shared activities. Outcomes will be (i) robust estimates of eligibility, consent and
recruitment rates with refined recruitment procedures; (ii) characterisation of the eligible population; (iii) a
standardised intervention with associated written materials, (iv) adherence and negative outcomes measures;
(v) preliminary estimates of adherence, acceptability, follow-up and missing data rates, along with refined
procedures; and (vi) description of standard treatment.
Discussion: Our study will provide important information on the nature of type 2 diabetes in adults with LD
living in the community, on the challenges of identifying those with milder LD, and on the possibilities of
evaluating a standardised intervention to improve self-management in this population.
Trial registration: Current Controlled Trials ISRCTN41897033 (registered 21 January 2013).
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Definition and case finding
The prevalence of type 2 diabetes varies markedly by ethni-
city and social factors including deprivation. Case finding
for service planning and for research is greatly facilitated in
the UK by a requirement for general practitioners (GPs) to
maintain a register of all patients with diabetes, remuner-
ated through the Quality Outcomes Framework (QOF) for
undertaking various health assessments on an annual cycle
(http://cks.nice.org.uk/diabetes-type-2). Currently in
the UK, approximately 5 % of the adult population is
recorded on these diabetes registers.
Individuals with learning disability (LD) are at par-
ticular risk of developing type 2 diabetes [1], but the ef-
fectiveness of self-management in this group remains
unclear. Identifying those with LD and diabetes would
facilitate an understanding of the size of the problem in
order to allow the implementation of effective manage-
ment strategies. This is a complex area because LD is not
straightforward to define and identify, especially at the
milder end of the spectrum. It can be defined statistically
based on test scores that typically show a negatively
skewed distribution. In those terms, it is often said that
2 % of the general population will have some degree of
LD (http://www.learningdisabilities.org.uk/help-information/
Learning-Disability-Statistics-/) [2, 3]. However, the pic-
ture becomes more complex when an element of func-
tional impairment in real-world activities is built into the
definition, partly because any functional deficit may not be
entirely attributable to intellectual impairment but to emo-
tional or social problems. Conversely, an adult with intel-
lectual impairment may not come to the attention of
statutory or non-statutory agencies if he or she is function-
ing independently or is well supported by family or some
other informal carer. The functional approach is now wide-
spread (http://www.rcn.org.uk/__data/assets/pdf_file/0006/
78765/003184.pdf; http://www.bps.org.uk/). It is esti-
mated that a minority (≤25 %) of the adult population
with LD is known to health or social services [4]. This
is unfortunate because it is apparent that adults with
LD have high rates of physical illness, and a recent re-
port highlighted their poor levels of healthcare [2, 5].
Supported self-management of long-term conditions
such as diabetes is now quite well established, although
its content and the intensity with which it is delivered,
have varied considerably between studies [6]. Current
self-management materials largely support information
provision with less emphasis on facilitating behavioural
change. Moreover, many adults with LD do not live in-
dependently even when they can be defined as living
outside hospital or residential care. This means self-
management must be negotiated not just with the
person with diabetes but with their supporter; there-
fore, considerable flexibility is needed to negotiate andimplement an intervention. For these reasons, there is
considerable preparatory work to do before a definitive
trial can be designed and even before a feasibility trial
can be undertaken. This paper describes the protocol
for the preparatory work for a definitive trial under-
taken within the OK Diabetes study.
Aims and objectives
The aims of Phase I of this study are as follows:
1. To develop and evaluate a method to identify
participants who have mild/moderate LD and type 2
diabetes who are not taking insulin and who might
be suitable for supported self-management, including
procedures for establishing capacity and consent,
and to characterise this population.
2. To develop a standardised but flexible intervention
supported by written materials to aid supported
self-management of diabetes, a simple measure of
adherence to the intervention, and to assess the
feasibility of delivering the intervention.
The aims of Phase II of this study are to undertake a
feasibility trial:
1. To assess the feasibility of (i) collecting and
recording a range of physiological, psychological,
behavioural and cost-effectiveness outcome
measures, (ii) maintaining the blind for subjective
outcomes, (iii) collecting data from medical
records and (iv) using the adherence measure to
assess delivery and use of self-management
techniques.
2. To develop a checklist of potential negative
outcomes and a related process for their collection,
with a preliminary assessment of the acceptability of
the intervention (via adherence, drop-outs and
negative outcomes such as distress and agitation)
and to provide a detailed description of what
treatment is delivered to each arm.
3. To estimate parameters needed for the design of a
definitive Phase III trial (for example, recruitment,
adherence and retention rates, and variability in
HbA1c, BP, BMI, and EQ-5D).
Methods/Design
Design
Phase I is a prospective case-finding survey involving 120
to 350 participants. Phase II is an individually-randomised
controlled feasibility trial of supported self-management
plus standard treatment versus standard treatment, involv-
ing 80 participants (and where possible their supporters).
Eligible, consenting participants will be randomised on a
1:1 basis and followed up for 6 months. Identified
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supporters, referrers and care providers cannot be blinded
to treatment allocation. Steps will therefore be made to
blind all aspects of outcome assessment carried out by re-
searchers. Data will be collected from medical notes, by
the nurse and by researcher interview. Where appropriate,
data will be used to inform whether it is feasible to design
a definitive, multicentre RCT.Setting
Three districts in West Yorkshire, centred in the cities
of Leeds, Bradford and Wakefield, were selected to take
part to maximise generalisability and provide a good test
of feasibility of recruitment. Service configurations vary
considerably across these three settings. In Leeds, most
type 2 diabetes cases are managed exclusively in primary
care, with referral to secondary care only for specific
problems. There is a tiered system for diabetes care in
Bradford, with almost half of the GP practices managing
insulin transfer, and several participating in collaborative
care of complex cases. In Wakefield, primary care dia-
betes services are supported by local commissioning ar-
rangements, where specialist teams tailor their work to
individual need. There are also a wide range of services
for people with LD in the social care and third sectors.Eligibility criteria
Participant eligibility will be assessed in stages (see Fig. 1
for details). Although we intend to recruit people with
LD and type 2 diabetes even if they live independently
and have no informal supporter, we expect the majority
will have a supporter.Inclusion criteria
The inclusion criteria are as follows:
1. Aged 18 years or over (Phase I and II)
2. Diagnosed with type 2 diabetes, controlled with diet
alone or hypoglycemic agents other than insulin
(Phase I and II)
3. Mild to moderate LD (Phase I and II)
4. Living in the community (not in a hospital setting)
(Phase I and II)
5. Up-to-date (ideally within 6 weeks of randomisation,
no maximum explicitly set) values of HbA1c and
BMI (Phase II)
6. Suboptimal diabetes control, defined as HbA1c>6.5 %
(equivalent to 48 mmol/mol) OR BMI>25 kg/m2 OR
physical activity below national guidelines (Phase II)Exclusion criteria
The exclusion criteria are as follows:1. Insufficient mental capacity to consent or to
participate in the research (Phase I and II)
2. LD acquired from disease in adult life, defined as 16
years or over, such as LD due to adult-onset dementia
or stroke (Phase I and II)
3. Type 1 diabetes, secondary diabetes (such as
steroids, pancreatitis, endocrine disorders etcetera)
and rare causes of monogenic diabetes (such as
maturity onset diabetes of the young) (Phase I and
II)
4. Referred for insulin (Phase I) or put on insulin
between identification and randomisation, or likely
to require insulin in the next 6 months (Phase II)
5. Declining further assistance with diabetes
self-management (Phase II)
A supporter will be defined as the main adult nomi-
nated by the supporter, by the participant or by a profes-
sional who knows that person, as providing practical
help and support in day-to-day living relevant to their
diabetes management. For Phase II an operational defin-
ition is ‘a key person in providing regular practical sup-
port in diabetes self-management, who is in contact with
the person with diabetes at least weekly’ and able to give
informed consent. It is recognised that there may be sev-
eral people involved with relevant aspects of a partici-
pant’s life. They may be included as “other helpers” in
self-management plans if desired by the participants but
will not be defined as a supporter.
Mild to moderate LD will be defined by a researcher-
led assessment of functional deficits (in daily activities,
educational and social attainment and support needs,
day-to-day cognitive functions of memory, knowledge)
attributable to primary or secondary/acquired cognitive
impairment. Mental capacity will be assessed by the re-
searcher, trained by the LD consultant, following guide-
lines from the 2005 Mental Capacity Act (http://
www.legislation.gov.uk/ukpga/2005/9/contents). Careful
note will be made of grounds for inclusion or exclusion
in each case using journaling techniques, recognising
that a challenge will be to identify people with mild LD
who are not already so-designated by themselves or
others and yet who might benefit from the intervention.
Participant identification and recruitment
All patients on registers in primary and secondary care will
be screened for referral by staff in a range of settings - in-
cluding GPs, primary care staff conducting QOF diabetes
or LD checks or in community diabetes teams, secondary
care staff in diabetes or specialist LD services, Local Au-
thority LD services, or third sector organisations. In
addition to screening QOF registers, general practices will
be provided with an electronic (that is, Read Code) search,
created by the research team, which identifies potentially
Screening: Via GP QOF diabetes registers, community diabetes teams, secondary care diabetes services & specialist LD services, LA 
and third sector organisations.
Referral to the study: Adults (aged 18 or over) with type 2 diabetes, with actual or suspected mild/moderate learning disability, not 
requiring insulin
Excluded: Aged <18 years; without type 2 diabetes, learning problems not attributable to Learning 
Disability, not willing to provide consent for researcher contact.
Face-to-Face Researcher Interview with Participant (and Supporter) Semi-structured interview to further assess 
eligibility, establish current diabetes management, preference for assistance with diabetes self-management, identify supporters,  obtain 
consent for further contact.
Approach for Participation in RCT: Meet eligibility criteria following referral/interview /medical record review and would like 
help with diabetes self-management; Consents to further contact
Excluded: Now on insulin or not living in the community, not willing to provide consent to a further 
face-to-face interview 
Face-to-face researcher Interview with Participant (and Supporter): Eligibility, Consent and Baseline 
assessment Semi-structured interview to confirm eligibility for the feasibility RCT ideally within 6 weeks of randomisation, assess 
capacity to consent to the feasibility RCT, obtain consent and collect quality of life, health economic measures, participant mood, identify 
supporter. Obtain consent to obtain baseline physical measures.
Phase 
I
Phase
II
Phone Contact with Participant and/or Supporter: Verbal consent obtained, approx. 1 week after a letter is sent giving 
info about the study, for a face-to-face interview. 
Medical Records Review This may be followed up by a phone call to the GP practice to coordinate collection of up-to-date routine 
bloods, if possible
Excluded: Not meeting referral inclusions; without mild to moderate Learning Disability, not living in 
the community, with insufficient mental capacity to consent to, or participate in, Phase I data collection, 
not willing to provide informed consent to Phase I data collection
Letter with PIS
Excluded: With learning problems acquired from disease in adult life, with secondary diabetes or rare 
causes of diabetes, will require insulin in the next 3 months, Type I diabetic
Excluded: Not eligible for Phase I, declining further help or contactLetter with PIS 
unless preference for 
phone contact
Phone contact with Participant and/or Supporter: Approx. 1 week after a letter is sent giving info about the study, the 
Researcher will confirm the participant does not require insulin and still lives in the community. If still potentially eligible, verbal consent will 
be obtained for a face-to-face interview with the Researcher 
Excluded: Not eligible, insufficient capacity to consent, not willing to provide baseline data or consent 
for the feasibility RCT
Face-to-Face nurse visit with Participant (and supporter): Where necessary Nurse confirms consent and explains 
tests required. If consented to, nurse takes bloods, BP, height, weight, and waist to hip ratio. If bloods refused alternative options offered, 
e.g. bloods taken at usual GP surgery
Excluded: Not willing to provide blood tests and unable to gain them via GP; No evidence of 
suboptimal diabetes control (i.e. HbA1c<6.5% AND BMI<25 AND physical activity within national 
guideline levels). 
RANDOMISED
Intervention: Supported self-
management plus standard treatment
Control: Standard treatment
6 month Follow-up Assessment
Completeness and variability in main outcomes; QL and health economic measures 
reported uptake and adherence, description of treatment received including medication 
use, negative outcomes and RUSAEs, routine bloods, withdrawals from treatment and 
follow-up, qualitative data, if necessary permission for bloods.
Final Analysis 
6 month Nurse Visit
Where necessary Nurse confirms consent and explains tests required. If consented to, 
nurse takes bloods, BP, weight, waist to hip ratio. If bloods refused alternative options 
offered, e.g. bloods taken at usual GP surgery
Fig. 1 Flow Diagram
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of which clinical staff will review. Once identified, referrers
will obtain and document consent from the potentialparticipant to pass on their contact details (or those of a
supporter if preferred) to the research team. A letter and
information sheet will then be sent from the research team
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followed up a week later by a telephone call where the
study can be discussed further. During the call, verbal con-
sent will be obtained for a face-to-face interview with the
researcher.
The first interview will use a standardised semi-
structured interview format designed to (i) discuss the
information sheet and obtain written or verbal (where ne-
cessary) informed consent for Phase I, (ii) obtain consent
to review medical records for routine clinical measures,
(iii) establish diabetes management, including diet and
physical activity, (iv) elicit preferences for further assist-
ance and consent to re-contact for Phase II, and (v) iden-
tify the role of supporters in diabetes management,
nominating a supporter to be involved in Phase II as ap-
plicable. Local sites or the research team will provide an
interpreter if either (or both) the participant or (and) sup-
porter is (are) not fluent in English. In the rare event that
no-one suitable is available, this will act as an exclusion
criterion. During the Phase II baseline interview, the re-
searcher will (i) further confirm eligibility (excluding sub-
optimal diabetes control where blood results are not yet
available), (ii) seek consent to participation in Phase II,
(iii) collect baseline data and, as appropriate, (iv) consent
for a nurse to visit and take bloods and other physical
measures prior to randomisation. If present and willing, a
supporter will also be consented into the study. The re-
searcher will send participants a certificate of participation
after the 6-month follow-up.
Registration and randomisation
Participants will be entered into Phase I at registration
and Phase II at randomisation. Consent is obtained prior
to registration and randomisation. All referrals that show
documented consent will be registered, using a secure,
automated 24-hour telephone registration service based
at the Clinical Trials Research Unit (CTRU), University
of Leeds. Following registration, researchers will follow
up with participants’ GPs to determine final eligibility
for Phase I via medical notes. If a participant meets the
eligibility criteria for Phase II, they will be randomised,
following informed consent and baseline assessment, on
a 1:1 basis to receive supported self-management plus
standard treatment or standard treatment using a secure,
automated 24-hour telephone randomisation service
based at the CTRU, ensuring allocation concealment. A
computer-generated minimisation algorithm incorporat-
ing a random element will be used, accounting for (i)
site (Leeds, Bradford, Wakefield), (ii) supporter (none,
not living with supporter, living with supporter), (iii)
HbA1c (≤48, 49 to 69 years of age, ≥70 mmol/mol), (iv)
BMI (≤25 or >25 kg/m2), and (v) physical activity (below,
or at or above national guidelines). The CTRU will in-
form the nurse, but not the researcher, of the outcomeof randomisation. The nurse will contact participants,
supporters and advocates as appropriate in the interven-
tion and control arm to explain the outcome and to make
an appointment with those in the intervention arm.
Interventions
At the start of the study, we expected much of the work
with people with LD to be under-taken through the in-
volvement of informal supporters who are already pro-
viding input and whom we would not wish to by-pass or
displace. This is in contrast to the usual pattern of sup-
port, where a professional or trained peer acts as a ther-
apist to help and encourage the nominated patient in
using the self-management materials. We will modify
the format of materials, creating more visual, accessible,
‘easy read’ materials more appropriate to those with lit-
eracy problems. The developed interventions are briefly
described below.
Supported self-management
Professional support will be arranged via a diabetes
nurse. Two dedicated research nurses will provide sup-
port to participants across sites. Supervision and training
will be given to the nurses by the intervention devel-
opers. The intervention has four standardised compo-
nents with associated materials; how they are delivered
will depend upon participant and supporter characteris-
tics and preferences:
1. Establishing the participant’s daily routines and
lifestyle: This includes current diet and activity
routines, participation on daytime social activities
or work, shopping and food preparation, current
self-reported health and self-management.
2. Identifying all supporters and helpers and their
roles: A key supporter will be identified where
possible, and their role in the life of the person
with diabetes. Key supporters and other helpers
will be given written information about the project
and if they agree to support a goal set by the
participant they will be given a written reminder of
their role.
3. Setting realistic goals for change: The main aim is to
avoid prescribing change in the way of good dietary
practice or other lifestyle change, but to support
goals suggested by the person with diabetes that are
specific, simple and achievable given the person’s
current routines and social support, and consonant
with their willingness to make change.
4. Monitoring progress against agreed upon goals: We
have devised a simple system that does not depend
on high levels of functional literacy. The outputs
will be collected by the nurse delivering the
intervention.
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ported self-management with the participant, explaining
how to use materials and suggesting initial actions and
activities. Further contact will be negotiated, but we an-
ticipate a total of three to four meetings of 30 to 60 mi-
nutes over 6 to 8 weeks, followed by telephone support
and advice, with the balance offered to the person with
diabetes decided by negotiation.
Standard treatment
All trial participants will receive standard treatment for
their diabetes. Different staff and services will be in-
volved in providing this care, as uncomplicated type 2
diabetes in the community is usually managed through
primary care.
Both groups
To ensure participants have a standardised minimum
level of care, we will provide standard information about
type 2 diabetes, made accessible for people with LD, to
all participants. This information will be selected from
resources already produced by the NHS, by Diabetes UK
or a LD charity and amended by the project team (with
permission of the creators). It will cover key areas already
identified as essential in diabetes self-management (that is,
diet, exercise, medication use, and feet and eye care). The
resource will be selected in collaboration with our Patient
and Public Involvement (PPI) collaborators. We will notTable 1 Phase I summary of assessments
Assessment (including who is involved)
Screening
Demographic data including (i) age, (ii) gender, and (iii) ethnicity
Preferred method of contact
Eligibility and consent
Eligibility (assessed by Referrer, Study Researcher; confirmed by Clinician), i
Documented consent to contact (Ref, Pa)
Verbal consent to interview (P, S, R)
Mental capacity to consent to Phase I (P, R)
Written consent to Phase I (P, S, R), including access to GP notes for QOF
Documented consent to re-contact (P, S, R)
Baseline data (P, S, R)
Presence and role of a supporter
Demographic data including (i) Household composition, (ii) type of housin
of support, (v) employment status, and (vi) first language
Current physical health state from QOF measures (HbA1c, BP, BMI, Q Risk)
Prescribed diabetes regime (medication)
Preferences for further assistance (P, S, R)
BP=Blood pressure, BMI = body mass index, HbA1c = glycated haemoglobin
aRef = Referrer, P = Participant, S = Supporter, R = Researcher; QOF, Quality Outcomotherwise attempt to influence the content of standard
treatment.
Data collection
The following will be collected during Phase I (Table 1):
Phase II assessments will be undertaken at the follow-
ing time points (see Table 2):
1. Medical notes review/check (prior to randomisation)
2. Pre-baseline phone call (prior to randomisation)
3. Baseline interview (prior to randomisation)
4. Nurse visit (where necessary, prior to randomisation)
5. 6-month follow-up interview and qualitative
interview
6. 6-month nurse/medical follow-up
with a guidance window of plus or minus 2 weeks at
follow-up (baseline interviews should take place no more
than 6 weeks prior to randomisation). If up-to-date Phase
I HbA1c and BMI are available from their GP (available
within the last 6 weeks) as established by the researcher,
records may be carried forward to the Phase II baseline.
Participants, and their supporters, will be followed up
directly by the researcher and, where appropriate, at sep-
arate visits by the nurse to collect blood and physical
measures, at 6-months post-randomisation. Following
the 6-month follow-up assessments, we will un-blind the
researchers so they can interview participants in the
intervention arm using a simple topic guide, followed byReferral Phone Face-to-face
interview
Medical
notes
X
X
ncluding reason for exclusion X X X X
X
X
X
X
X
X X
g, (iii) marital status, (iv) nature X
X
X X
X
es Framework; GP, general practitioner
Table 2 Phase II baseline and follow-up assessments
Med notes
review/check
Pre- baseline
phone call
Baseline
interview
Nurse
baseline
6 month medical/
nurse follow-up
6 month follow-up
interview
Med notes
follow-up
Eligibility and consent
Presence and role of a supporter and/or
research advocate
X X
Mental capacity to consent to Phase II (P, R) X
Eligibility for Phase II (assessed by Study
Researcher)
X X X
Consent for Phase II (P, S, Ra) X
Follow-up data (P, S, R, N)
Negative outcomes X
Related and Unexpected Serious Adverse
Events
X
Hospital attendances X
Current physical health state (for example,
HbA1c, BP, BMI, weight, BP, HbA1C,
cholesterol, HDL/ LDL triglycerides, Urea
and Electrolytes, waist to hip ratio (N)
X X X
Thyroid function, height (N) X
Q Risk, Retinal screening, Medication,
Serum creatinine, micro-albuminuria
X
Details of Treatment Received X
Adherence to the intervention (N) X
Prescribed diabetes regime (diet, exercise) X
Questionnaires (completed at Researcher visit)
Health Economics questionnaire (P and S
interviewer administered) to cover health
and social care costs, participant and
supporter expenses and productivity costs
X X
Participant (P) mood (questions taken from
Phase I)
X X
Health-related quality of life (EQ5D) (P) X X
BP=Blood pressure, BMI = body mass index, HbA1c = glycated haemoglobin
aP, Participant; S, Supporter; R, Researcher; N, Research Nurse
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positive and negative experiences of implementing the
intervention. All participants who enter the study will be
considered part of the intention-to-treat population, and
efforts will be made to follow them up wherever appro-
priate. If there are no up-to-date medical records, then
the nurse will collect weight, BP, waist-to-hip ratio
(using a standard protocol), HbA1C, cholesterol, HDL/
LDL triglycerides, urea and electrolytes. Wherever pos-
sible, the nurse visit will be undertaken blind.
Health economics
In Phase I, we will develop data-collection forms to assess
the cost effectiveness of the self-management intervention
in a definitive trial, field testing them with service users
from our PPI collaborators. It is generally argued that a
societal perspective is adopted in economic evaluation of
self-management interventions, as patients’ costs are likely
to be more important than with more conventionalinterventions [7]. Thus, drawing on existing literature in
LD and diabetes, the forms will identify patient resource
use from the perspective of the health and social care sec-
tor and from a wider societal perspective. They will in-
clude the costs of health and social care (service provision
and use of other health and social care services) and take
into account the productivity costs (time away from work)
and out-of-pocket expenditures incurred by the patients
(for example, travel expenses, over-the-counter medicines
and supplements and additional costs/savings of any diet-
ary changes). Burden to the supporter will also be consid-
ered (for example, productivity costs and out-of-pocket
expenses). In addition to participant/supporter-completed
data, the resources associated with development and de-
livery of the intervention will be recorded. These will be
based on routine data such as administrative records and
participant records, as well as a detailed description of the
development process. For both sets of data, unit costs for
health service resources will be obtained from national
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ence cost database. If national unit costs are unavailable,
finance departments of trusts participating in the study
will be asked to provide local cost data. The mean of these
costs will be used as the unit cost estimate in the analysis.
In line with NICE recommended practice, any cost effect-
iveness analysis will require quality-adjusted life years
(QALYs) and utility weights for each health state observed
in a trial population. A 2001 HTA report that considered
general health status measures for cognitively impaired
populations found the EQ-5D to be superior compared
with other preference-based measures of health [8]. We
will explore use of the EQ-5D for participants and for sup-
porters/informal carers (not including ‘paid’ supporters)
and of obtaining details of resources used from GPs.
Outcomes
At the end of Phase I, we will: (i) have a robust estimate
of the number of people who meet our eligibility criteria,
and the number willing to consider change and to par-
ticipate in further research, (ii) be able to characterise
the population in terms of important characteristics such
as diabetes control, living circumstances and role of sup-
porters in diabetes management, (iii) have developed our
intervention materials and adherence measures and
field-tested them for acceptability in service users from
our PPI collaborators, and iv) identified existing infor-
mation resources on diabetes self-management suitable
for people in our target group. Phase II will inform the
choice of primary outcome for the definitive trial. The
outcomes listed below relate to feasibility of recruitment,
retention, intervention delivery and outcome collection.
Recruitment and retention: (i) number of Phase I
participants screened for eligibility for Phase II; (ii)
proportion of Phase I participants screened found
to be eligible for Phase II; (iii) proportion of Phase I
participants that consent to Phase II out of those
found eligible; (iv) proportion of Phase I participants
randomised out of those that consent (prior to
medical notes review); (v) proportion of randomised
participants that have a supporter; (vi) reasons for
non-participation (participant and supporter); (vii)
method of identification for randomised participants
and supporters; and (viii) proportion of randomised
Phase II participants with all the required baseline and
follow-up assessments completed, number of physical
measures refused, number of withdrawals from follow-up
data collection, reasons for withdrawal, number of losses
to follow-up.
Intervention delivery: (i) proportion of participants
randomised to intervention attending at least one
intervention session with the nurse, (ii) number of
drop-outs from the intervention, reasons for drop outs,(iii) agreed upon method of measuring participant,
supporter and nurse adherence to the intervention,
including uptake/adherence rates and assessment of the
feasibility of using a standardised measure, (iv) detailed
description of what treatment was delivered to and
received by each arm, including a comparison of
standard treatment across arms plus an assessment
of feasibility of collecting data on standard treatment
pathways, and (v) preliminary assessment of the
acceptability of the intervention, including negative
outcomes, hospital attendances and RUSAEs.
Outcome data collection: (i) assessment of the
feasibility of blinding researchers and follow-up nurse
to treatment allocation, (ii) proportion of participants
who refuse physical measures with available and timely
QOF data at baseline and (if necessary) at their
follow-up assessments, (iii) assessment of the feasibility
of collecting data on adherence to the intervention and
the standard information, (iv) completion rates for
other data collected, including assessment of the
feasibility of collecting health economics data
(for example, participant EQ-5D, NHS and supporter
costs, medication use), and (v) missing item level data
on self-reported questionnaires as collected by the
researcher.
Statistical outcomes: (i) variability of candidate
primary/secondary outcomes at 6 months
post-randomisation (HbA1c, BP, BMI, waist to hip
ratio, EQ-5D, vascular/micro-vascular risk markers,
participant mood), (ii) proportion of participants
classed as abnormal on standard criteria for medical
markers, and (iii) assessment of the potential for
contamination within households.
Qualitative outcomes: (i) positive and negative
experiences of supported self-management, (ii)
perceptions of standard information resource and
experience of being in control arm, (iii) further detail
on standard treatment in all participants, and (iv)
modified implementation plan for the definitive trial.
Monitoring adherence
Steps taken to ensure consistency in the use of the inter-
vention will be recorded (training and supervision ses-
sions with nurses, annotation of the manual by nurses,
other experience and training in diabetes or LD care
prior to Phase II). Provider adherence will be recorded
by the nurse recording (i) dates of treatment meetings,
(ii) all telephone contacts, (iii) materials provided (for
example, goal-setting sheets, weekly planning and self-
monitoring charts), (iv) confirmation that a named sup-
porter (if there is one) has received an information pack.
Participant and supporter adherence will be recorded
by the nurse. Evidence of the use of techniques of self-
management will be identified by copying and/or
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ning charts; self-monitoring charts. These materials
will be independently reviewed by a member of the re-
search team, and data will be entered onto a form to
detail use of each of the identified elements of the
intervention. We will develop a coding and scoring sys-
tem, with a global rating of overall adherence on a short
ordinal scale. We will supplement quantitative data with
qualitative interviews with all trial participants.
Sample size
Phase I
We aim to interview up to 350 people meeting eligibility
criteria, based on the assumption that there are 1,400
people across the three sites in the target population (2
% of the population with type 2 diabetes), with an antici-
pated 50 % GP involvement and 50 % eligible adults.
This will allow us to estimate the proportion eligible of
the target population (that is, conservatively 50 %) for
Phase II to at least within 5.2 % with a two-sided 95 %
confidence interval. If we recruit fewer participants, the
width of this confidence interval will increase, reducing
precision to 6.9 % if we recruit 200.
Phase II
To address the feasibility objectives, we plan to recruit
80 participants, randomised on a 1:1 basis, to obtain
follow-up data on at least 30 participants per arm, as
recommended by Lancaster et al. [9]. This assumes loss
to follow-up will be no greater than 25 % at 6 months.
Planned analyses
The statisticians are responsible for the statistical ana-
lyses for Phase I and II. The health economists are re-
sponsible for health economic analyses. A statistical
analysis plan will be written and agreed before any ana-
lysis is undertaken, with any changes, with reasons, to
the finalised plan documented.
Interim analyses
No interim analyses are planned.
Phase I analysis
To evaluate the case-finding method, the pattern/preva-
lence of uncertainty during eligibility assessment, method
of participant identification, contacts including number,
duration, and type, duplicate referrals and clusters of refer-
rals will be summarised overall and by referrer role and re-
gion, where appropriate. To provide robust estimates of
eligibility, screening, referral, interview, eligibility, capacity,
consent and registration rates will be reported, with con-
sent sub-divided into those willing to consider change and
those willing to participate in further research. The eligible
population will be characterised based upon the summaryof diabetes control, demographics, living circumstances,
and presence and involvement of a supporter in diabetes
management. Candidate outcome measures of diabetes
control available in routine care will be summarised in
terms of data quality, and acceptability will be assessed by
the presence of missing items.
Phase II analysis
Analysis will be conducted, when all the available data
has been received and cleaned, on the intention-to-treat
sample, including all randomised participants in the arm
to which they were randomised. The flow of participants
and supporters through the study will be depicted in
CONSORT diagrams. Recruitment, uptake and adher-
ence rates will be reported overall, by arm and by
recruiting site. Six-month follow-up rates will be re-
ported for each outcome (for participant and supporter,
self-reported measures and those collected from routine
GP data sources), overall, by arm and site. The candidate
primary outcomes for a definitive RCT of HbA1c, BP
and BMI will be summarised overall and by arm at base-
line and 6 months and for the intervention arm by ad-
herence to the manual at 6 months. Means and SDs, or
medians and IQRs, will be presented, depending on the
distribution, together with 95 % CIs. This will provide
more accurate estimates of variability, recruitment,
follow-up and adherence needed to assess the feasibility
of recruiting into, and inform the sample size estimation
of, a definitive trial. The feasibility and quality of collect-
ing blood tests, vascular risk markers and markers of
microvascular disease by the nurse will be reported and
the proportion and nature of any missing data on these
outcomes. The presence and quality of data collected on
other outcomes will also be summarised, including ad-
herence to the intervention at 6 months. This will help
to inform the modes of data collection and the instru-
ments used in a definitive trial. Outcomes of participant
mood, negative outcomes and health-related quality of
life, changes in treatment and patient and supporter/in-
formal care will be reported with means/SDs, medians/
IQRs or frequencies/proportions, depending on their
distributions, together with 95 % CIs at baseline and 6
months both overall and by arm. The outcome measure
relating to acceptability and uptake of the intervention
will be assessed by the presence of missing items in the
records of participants randomised to receive supported
self-management.
Economic analysis
Whilst the primary aim of Phase II is to test the feasi-
bility of data collection for any subsequent trial, ana-
lysis of the data collected will include descriptive
statistics of the resources used. Within this Phase II
analysis we will follow the NICE methods guidance [10]
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social services would be taken but additional analysis
would adopt a societal perspective. A summary of the
trial design is included as a flow diagram below (see
Fig. 1).
Ethical considerations
Ethical approval was granted for the study by the Yorkshire
and Humber Research Ethics Committee (Reference: 12/
YH/0304). We will include in both phases only those with
the capacity to consent to the research, and in Phase II
only those with the capacity to also undertake an element
of self-management. We will also attempt to obtain con-
sent from a supporter when that person supports diabetes
self-management and is willing to be involved in the study.
They will consent to assist the person with diabetes in any
changes agreed during the intervention, and to participate
as agreed in the project by, for example, assisting in collec-
tion of materials. Consent will be reassessed by the re-
searcher and nurse at follow-up. The researcher will
receive advice and support in this from third sector part-
ners, and will be familiar with standard guidance on the
topic [11]. If the participant agrees to participate then writ-
ten informed consent will be obtained. Verbal consent will
be obtained (where necessary) only when consent is clearly
given but the participant cannot provide a signature or ini-
tials. Each consenting participant will be offered contact
with a research advocate, who is independent of the re-
search team. The advocate’s role is to provide independent
support to participant’s regarding their participation
throughout the trial and follow-up, including, for example
a decision to withdraw from the research.
Trial governance
The Project Management Group (PMG), comprising the
Chief Investigator, project manager, co-investigators, mem-
bers of 3rd sector organisations (see below) and CTRU
team will meet monthly and is responsible for the clinical
set-up, on-going management and for the interpret-
ation of results. The Trial Steering Committee (TSC),
with independent Chair, will meet 6 monthly and pro-
vide overall supervision of the project, including trial
progress, adherence to protocol, safety and consider-
ation of new information.
Public and patient involvement
We have worked closely, to develop this protocol, with
two third sector organisations that represent the needs
of people with LD in our region - supported by a grant
from our local Research Design Service - People in Ac-
tion (http://www.peopleinaction.org.uk/), and Tenfold
(http://www.tenfold.org.uk/). During implementation of the
project we will continue to work with both these organisa-
tions and with easy on the i (http://www.easyonthei.nhs.uk/),the information design service in the Learning Disability
Service at Leeds and York Partnership NHS Foundation
Trust.
Discussion
We anticipate three main challenges in the delivery of
this project. First, patient identification and recruitment
may be difficult: although neither diabetes (prevalence
4–5 %) nor LD (prevalence 2 %) is very rare, in combin-
ation they have a prevalence of approximately 0.1 %. In a
GP practice with an adult list size of 10,000 that means
a pool of only 10 patients, from which there will also be
exclusions due to patients having type 1 diabetes, or type
2 diabetes treated with insulin, insufficient mental cap-
acity, not living independently in the community, or be-
cause they do not give consent. We will seek to maximise
participation by developing and testing several methods of
recruitment in primary care simultaneously, by seeking re-
ferral from community services (in dentistry, dietetics and
podiatry for example) and secondary care and by active
collaboration with 3rd sector organisations.
A second challenge is that we know very little about
how our target population manage type 2 diabetes or,
as a group, what their diabetes control is like. This
means that it is difficult to specify in detail the form
and content of our intervention until we have recruited
reasonable numbers into Phase 1, although the main
components are clear as outlined above. Third is the
choice of outcome measures. Our proposed primary
outcome measure is HbA1c as it is the most common
outcome in diabetes trials, and a cost-effective inter-
vention will need to demonstrate an effect on this im-
portant marker of risk. However, other important
determinants of longer-term outcomes in diabetes, such
as diet and physical activity levels, are notoriously diffi-
cult to record reliably in the general population and are
likely to be even harder in those with a LD. An import-
ant output of this study will be to establish what can be
reliably and accurately collected in the way of second-
ary outcomes - including those related to the economic
analysis.
Trial status
Recruitment of participants is ongoing in three study
districts in West Yorkshire, centred in the cities of
Leeds, Bradford and Wakefield.
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